Ondansetron Accordpharma

Ondansetron, the active ingredient in Ondansetron Accordpharma, is a 5-HT3 receptor antagonist presented as a 5 mg oral tablet for systemic use. It treats and prevents nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and pediatric patients. GNH USA supplies Ondansetron Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondansetron Accordpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron Accordpharma is a selective 5‑HT3 receptor antagonist used to manage nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes in cancer patients. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms during radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures. - Hyperemesis gravidarum (off‑label): may be considered when conventional therapies are ineffective, under specialist supervision.

Common Side Effects: - Headache: mild to moderate headache may occur. - Constipation: reduced bowel movements are reported. - Diarrhoea: occasional loose stools. - Fatigue: feeling of tiredness or low energy. - Dizziness: transient light‑headedness. - Injection site reactions (if applicable): mild pain or erythema.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation leading to irregular heart rhythm. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, tremor, hyperreflexia when combined with serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Neuroleptic malignant‑like syndrome: rare, high fever and muscle rigidity. - Vision changes: blurred vision or visual disturbances.

Ondansetron should be used with caution in patients with known cardiac conduction abnormalities or electrolyte disturbances.

- Cardiac monitoring: perform ECG in patients at risk for QT prolongation. - Electrolyte assessment: correct hypokalemia, hypomagnesemia, or hypocalcemia before use. - Drug interactions: review concomitant medications that may affect cardiac rhythm. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgment. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medications that influence cardiac rhythm or serotonergic pathways.

Major Interactions (Avoid): - Anti‑arrhythmic agents (e.g., amiodarone, quinidine): increase risk of QT prolongation. - Certain antipsychotics (e.g., haloperidol, ziprasidone): additive effect on QT interval. - Serotonergic drugs (e.g., SSRIs, MAO inhibitors): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise ondansetron plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Digoxin: potential increase in serum digoxin concentrations. - Oral contraceptives: possible reduction in hormonal efficacy. - Theophylline: may enhance theophylline toxicity.